Validation of Wistar-Kyoto rats kept in solitary housing as an animal model for depression using voxel-based morphometry

Yoshii, Takanobu; Oishi, Naoya; Sotozono, Yasutaka; Watanabe, Anri; Sakai, Yuki; Yamada, Shunji; Matsuda, Ken-Ichi; Kido, Masamitsu; Ikoma, Kazuya; Tanaka, Masaki; Narumoto, Jin

doi:10.1038/s41598-024-53103-2

Cited by 1 publication

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The administration of ketamine after eight days resulted in a complete reversal of symptoms. The model of CMS applied to the WKY rat line can be considered a valid animal model of TRD [13,25,26].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of New Approaches to Depression Treatment Using an Animal Model of Pharmacoresistant Depression

Zvozilova,

Bukatova,

Koprdova

et al. 2024

IJMS

View full text Add to dashboard Cite

Depression is emerging as the predominant psychiatric disorder globally. Despite the wide availability of antidepressants, up to 30% of patients exhibit poor response to treatment, falling into the category of treatment-resistant depression (TRD). This underscores the need for the exploration of novel therapeutic options. Our work aims to study the effect of chronic administration of the pyridoindole derivative SMe1EC2M3, a triple reuptake inhibitor, and the combination of zoletil and venlafaxine under conditions of stress induced by a 4-week chronic mild stress (CMS) procedure in Wistar-Kyoto male rats as an animal model of TRD. Therefore, we investigated the possible effect of the selected compounds in four experimental groups, i.e., stress + vehicle, stress + venlafaxine, stress + zoletil + venlafaxine and stress + SMe1EC2M3. The following variables were assessed: anhedonia in sucrose preference test (SPT), spontaneous locomotion and exploration in open field test (OF), anxiety-like behavior in elevated plus maze test (EPM), motivation and depressive-like behavior in forced swim test (FST) and nociception in tail flick test. We also evaluated cognition, particularly recognition memory, in the novel object recognition test (NOR). Sucrose preference was significantly increased in the SMe1EC2M3 group (p < 0.05) in comparison with the venlafaxine animals. In the OF, we observed a significantly higher number of entries into both the central and peripheral zones in the venlafaxine (p < 0.05 central zone; p ≤ 0.05 periphery zone) and SMe1EC2M3 (p < 0.05 central zone; p < 0.05 periphery zone) groups compared to the venlafaxine + zoletil group. SMe1EC2M3 was able to significantly increase the time of climbing in FST (p < 0.05) in comparison with the venlafaxine and control groups. The NOR test revealed a significantly higher discrimination ratio in the SMe1EC2M3 group (p < 0.05) compared to the control and venlafaxine groups. Analyses of the tail flick test showed a significant increase in reaction time to painful stimuli in the SMe1EC2M3 group (p < 0.05) in comparison to both the control and venlafaxine groups. Our findings suggest that SMe1EC2M3 has the potential to ameliorate some behavioral changes associated with TRD, and the venlafaxine + zoletil combination treatment was not a promising treatment alternative in the animal model of TRD.

show abstract

Section: Introductionmentioning

confidence: 99%